Allergen-specific immunoglobulin E (sIgE) (sIgE)

Allergen-specific immunoglobulin E (sIgE) is a specialized class of antibody that plays a central role in the pathophysiology of Type I hypersensitivity reactions [1]. Produced by B cells in response to environmental allergens, sIgE circulates in the blood and binds with high affinity to FcεRI receptors on the surface of mast cells and basophils [2]. Upon subsequent exposure to the specific allergen, the allergen cross-links the receptor-bound sIgE, triggering the immediate release of inflammatory mediators such as histamine, leukotrienes, and cytokines [1][2]. This process leads to the clinical manifestations of allergic diseases, including asthma, rhinitis, and anaphylaxis [2]. Therapeutic targeting of IgE, primarily through monoclonal antibodies like Omalizumab, aims to sequester free IgE and downregulate receptor expression on effector cells, thereby reducing the allergic inflammatory cascade [3][4]. Monitoring sIgE levels is a standard diagnostic tool for identifying specific sensitivities and guiding personalized treatment strategies in allergic patients [5].

Other names

Specific IgEAllergen-specific IgE antibodyAntigen-specific IgE

Neutralization of free IgE by binding to the Fc region (Cε3 domain), thereby preventing its interaction with the high-affinity IgE receptor (FcεRI) on effector cells like mast cells and basophils [3][4].